A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LUCENT 2
- Sponsors Eli Lilly and Company
- 02 Sep 2019 Planned End Date changed from 22 Mar 2022 to 8 Jun 2023.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 17 Oct 2018 Planned primary completion date changed from 30 Mar 2021 to 15 Jun 2021.